Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study-Reference-Cited by-同舟云学术

Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study

Published:2020-11 Issue: Volume: Page:
ISSN:1699-258X
Container-title:Reumatología Clínica
language:en
Short-container-title:Reumatología Clínica

Author:

Rosas José,Liaño Francisco Pasquau,Cantó Mónica Llombart,Barea José María Carrasco,Beser Amparo Raga,Rabasa José Tomás Algado,Adsuar Francisco Martínez,Auli Brian Vila,López Isabel Fernández,Sainz Ana María Garijo,Ramis Pere Esquerdo,Pérez Laura Ruiz,Rebollo Mª Luisa Navarrete,Lorido Raquel Hernández,Escolar Laura Gómez

Funder

Association for Research in Rheumatology of the Marina Baixa

Publisher

Elsevier BV

Subject

Rheumatology

Reference31 articles.

1. COVID-19: consider cytokine storm syndromes and immunosuppression;Mehta;Lancet,2020

2. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia;Lin;Emerg Microbes Infect,2020

3. Coronavirus infections and immune responses;Li;J Med Virol,2020

4. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies;Conti;J Biol Regul Homeost Agents,2020

5. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality;Zhang;Int J Antimicrob Agents,2020

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City;Open Forum Infectious Diseases;2023-08-01

2. An update on drug-drug interactions for care of the acutely ill in the era of COVID-19;American Journal of Health-System Pharmacy;2023-06-27

3. Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19;Clinical Immunology;2023-06

4. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2;MedComm;2023-05-14

5. Role of baricitinib in COVID-19 patients: A systematic review and meta-analysis;World Journal of Meta-Analysis;2023-04-18